Author details

Full Name

Rintaro Hashizume

Affiliation

ORCID

Career Start Year

1996

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37252797	Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3/4-COMPASS epigenetic regulator mutations.	J Clin Invest	2023
36335802	The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science.	Neoplasia	2023
36759517	FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells.	Nat Commun	2023
37444539	WDR82-Mediated H3K4me3 Is Associated with Tumor Proliferation and Therapeutic Efficacy in Pediatric High-Grade Gliomas.	Cancers (Basel)	2023
35247919	Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors.	Mol Cancer Ther	2022
35395831	A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis.	Acta neuropathologica communications	2022
35524725	A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of H3K27M.	GLIA	2022
36305747	Epigenome Programming by H3.3K27M Mutation Creates a Dependence of Pediatric Glioma on SMARCA4.	Cancer Discov	2022
36274161	Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.	Acta Neuropathol Commun	2022
36410047	Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma.	Journal of Medicinal Chemistry	2022
36185807	Immunotherapy approaches for the treatment of diffuse midline gliomas.	OncoImmunology	2022
36599085	Intranasal delivery of nanoliposomal SN-38 for treatment of diffuse midline glioma.		2022
34693287	Fifteen-year trends and differences in mortality rates across sex, age, and race/ethnicity in patients with brainstem tumors.	Neuro-Oncology Advances	2021
33471107	Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.	Neuro Oncol	2021
34345820	The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma.	Neurooncol Adv	2021
33272983	Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.	Clin Cancer Res	2021
31225627	ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.	Neurosurgery	2020
32165429	Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.	Clin Cancer Res	2020
33086074	Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG.	Cell Rep	2020
32678903	LSD1 inhibition in pHGG: the key to unleashing immunotherapy?	Neuro-Oncology	2020
32674144	Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (EZH2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma.	Neurosurgery	2020
31345255	Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy.	Acta neuropathologica communications	2019
32039031	MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas.	Frontiers in Oncology	2019
30649490	Molecular and translational advances in meningiomas.	Neuro Oncol	2019
31227500	Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma.	Clin Cancer Res	2019
31005631	Global Reduction of H3K4me3 Improves Chemotherapeutic Efficacy for Pediatric Ependymomas.	Neoplasia	2019
30842251	Potent Antineoplastic Effects of Combined PI3KÎ±-MNK Inhibition in Medulloblastoma.	Molecular Cancer Research	2019
31201162	Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.	Cancer Res	2019
30833574	ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.	Nat Commun	2019
29785026	Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.	Nat Med	2018
30174560	Measuring Tumor Metabolism in Pediatric Diffuse Intrinsic Pontine Glioma Using Hyperpolarized Carbon-13 MR Metabolic Imaging.	Contrast Media Mol Imaging	2018
30111355	CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response.	Acta Neuropathol Commun	2018
30061363	MELK Inhibition in Diffuse Intrinsic Pontine Glioma.	Clin Cancer Res	2018
30340042	Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy.	Cell	2018
29170909	New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model.	J Neurooncol	2018
28059591	Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies.	Epigenetics	2017
28592748	Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma.	Neurologia Medico-Chirurgica	2017
28321824	Therapeutic Hypothesis Testing With Rodent Brain Tumor Models.		2017
28522693	Histone H3.3K27M Represses to Accelerate Gliomagenesis in a Murine Model of DIPG.	Molecular Cancer Research	2017
28355568	A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2.	Cell Rep	2017
29138278	A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism.	Genes Dev	2017
29340047	Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma.	Oncotarget	2017
27212051	Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas.	Current Neuropharmacology	2017
28263307	Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.	Nat Med	2017
27848137	Combined BRAF<sup>V600E</sup> and MEK blockade for BRAF<sup>V600E</sup>-mutant gliomas.	J Neurooncol	2017
26675675	Imidazoquinolines: Recent Developments in Anticancer Activity.	Mini-Reviews in Medicinal Chemistry	2016
27370397	Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.	Neuro Oncol	2016
26782702	Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.	J Neurooncol	2016
27217440	BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.	Clin Cancer Res	2016
26863490	Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma.	Journal of Visualized Experiments	2016